(19)
(11) EP 4 577 306 A1

(12)

(43) Date of publication:
02.07.2025 Bulletin 2025/27

(21) Application number: 23761808.7

(22) Date of filing: 23.08.2023
(51) International Patent Classification (IPC): 
A61P 35/00(2006.01)
C07K 16/28(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2878; C07K 2317/75; C07K 2317/76; A61K 2039/505; A61K 2039/507; C07K 2317/31; A61P 35/00
(86) International application number:
PCT/EP2023/073074
(87) International publication number:
WO 2024/042104 (29.02.2024 Gazette 2024/09)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 26.08.2022 US 202263401290 P

(71) Applicant: Merck Patent GmbH
64293 Darmstadt (DE)

(72) Inventor:
  • XU, Chunxiao
    Billerica, MA 01821-3936 (US)

(74) Representative: Merck Patent Association 
Merck Patent GmbH
64271 Darmstadt
64271 Darmstadt (DE)

   


(54) COMBINATION CANCER TREATMENT COMPRISING AN ANTI-MSLN/CD137 ANTIBODY AND PD-1/PD-L1 INHIBITOR